Hundreds of millions of people worldwide still need help
Approval timeline is estimated for late 2026 or 2027, making it unavailable for immediate use but worth watching closely
patents keep generics out until around 2031 or 2035, maintaining Novo Nordisks exclusivity and high prices Bookmark CommentsGo to comments Affordable, regulated versions of Ozempic, the well-known diabetes and weight-loss shot from Novo Nordisk, are about to hit markets around the world, which could shake up the obesity drug scene
Its crucial to start with a 2.5 mg dose once weekly, gradually increase to 5 mg after four weeks, and adjust further based on your glycemic response and individualized goals
Reported weekly weight-loss differences over placebo were small (in the range of -0.06 to -0.15 kg/week, depending on dose)